Invokana hits endpoints in cardiovascular trial
admin 13th June 2019 Uncategorised 0A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
More: Invokana hits endpoints in cardiovascular trial
Source: News
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
More: Invokana hits endpoints in cardiovascular trial
Source: News
© 1994 - 2026 B.M. Pharmaceuticals